Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer

New England Journal of Medicine

Volumn 366, Issue 16, 2012, Pages 1477-1488

  James, Nicholas D ^a   Hussain, Syed A ^a,b   Hall, Emma ^c   Jenkins, Peter ^d   Tremlett, Jean ^e   Rawlings, Christine ^f   Crundwell, Malcolm ^g   Sizer, Bruce ^h   Sreenivasan, Thiagarajan ⁱ   Hendron, Carey ^a   Lewis, Rebecca ^c   Waters, Rachel ^c   Huddart, Robert A ^c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

^e UK   (United Kingdom)

^f TORBAY AND SOUTH DEVON NHS FOUNDATION TRUST   (United Kingdom)

^g ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^h ESSEX COUNTY HOSPITAL   (United Kingdom)

ⁱ UNITED LINCOLNSHIRE HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; MITOMYCIN C;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BLADDER CANCER; BLADDER CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GRADING; CANCER INVASION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HAZARD RATIO; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION; UROGENITAL TRACT DISEASE;

EID: 84859880855     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1106106     Document Type: Article

References (22)

1. GLOBOCAN 2008: cancer incidence, mortality and prevalence worldwide in 2008. Lyon, France: International Agency for Research on Cancer (http://globocan.iarc.fr).
2. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859-66. [Erratum, N Engl J Med 2003;349:1880.] (Pubitemid 37025405)
3. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666-75. (Pubitemid 32120143)
4. Rödel C, Grabenbauer GG, Kühn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002;20:3061-71. (Pubitemid 34791095)
5. Cooke PW, Dunn JA, Latief T, Bathers S, James ND, Wallace DM. Long-term risk of salvage cystectomy after radiotherapy for muscle-invasive bladder cancer. Eur Urol 2000;38:279-86. (Pubitemid 30665954)
6. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999;340:1154-61. [Erratum, N Engl J Med 1999;341:708.] (Pubitemid 29177874)
7. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144-53. [Erratum, N Engl J Med 1999;341:708.] (Pubitemid 29177873)
8. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340:1137-43. (Pubitemid 29177872)
9. UKCCCR Anal Cancer Trial Working Party. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil and mitomycin. Lancet 1996;348:1049-54.
10. Coppin CM, Gospodarowicz MK, James K, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. J Clin Oncol 1996;14:2901-7. (Pubitemid 26371447)
11. Hussain SA, Moffitt DD, Glaholm JG, Peake D, Wallace DM, James ND. A phase II study of synchronous chemoradiotherapy for locally advanced bladder cancer. Br J Cancer 2001;85:16.
12. Idem. A phase I/II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer. Ann Oncol 2001;12:929-35.
13. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscleinvasive bladder cancer: a randomised controlled trial. Lancet 1999;354:533-40. [Erratum, Lancet 1999;354:1650.]
14. International Union against Cancer. TNM classification of malignant tumours. 6th ed. New York: Wiley-Liss, 2002.
15. National Cancer Institute. Common Toxicity Criteria, version 2 (http://www.eortc.be/services/doc/ctc/ctcv20-4-30-992.pdf).
16. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-6.
17. Rubin P, Constine LS, Fajardo LF, Phillips TL, Wasserman TH. Overview: Late Effects of Normal Tissues (LENT) scoring system. Int J Radiat Oncol Biol Phys 1995;31:1041-2.
18. Pavy JJ, Denekamp J, Letschert J, et al. Late effects toxicity scoring: the SOMA scale. Radiother Oncol 1995;35:11-5.
19. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2011;28:1061-8.
20. Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 2008;299:1914-21. (Pubitemid 351574921)
21. Olivatto LO, Cabral V, Rosa A, et al. Mitomycin-C- or cisplatin-based chemoradiotherapy for anal canal carcinoma: long-term results. Int J Radiat Oncol Biol Phys 2011;79:490-5.
22. Hoskin PJ, Rojas AM, Bentzen SM, Saunders MI. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol 2010;28:4912-8.